JRC Publications Repository

JRC Publications Repository >

Browsing by Author APOSTOLIDIS Christos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 95 to 114 of 139
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2009Radioimmunotherapy of Breast Cancer Metastases with Alpha-Particle-emitter 225Ac: Comparing Efficacy with 213Bi, 90YSONG Hong; HOBBS Robert F.; VAJRAVELU Ravy; HUSO David L.; ESAIAS Caroline; APOSTOLIDIS Christos; MORGENSTERN Alfred; SGOUROS GeorgeArticles in Journals
2009Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAbPFOST B.; MORGENSTERN Alfred; SEIDL C.; BRUCHERTSEIFER Frank; AUTENRIETH M.; APOSTOLIDIS Christos; ABBAS Kamel; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2001Radiopeptide Therapy with Cholecystokinin(CCK)-B/Gastrin Receptor Ligands Labeled with Auger/Conversion Electron-versus alpha- or Conventional beta Emitters.BEHR T.m.; BEHE M.; ANGERSTEIN C.; STABIN M.g.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F.; BECKER W.Contributions to Conferences
2000Radiopeptide Therapy with Cholecystokinin-B/Gastrin Receptor Ligands: Dose-Limiting Toxicity and Therapeutic Efficacy of Auger / Conversion Electron (111-In, 140-Nd) vs alpha(213-Bi) or Conventional beta(90-Y, 153-Sm) Emitters.BEHR T.m.; BEBE M.; STABIN M.g.; ANGERSTEIN C.; MACH R.; HAGEMANN L.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F., et alContributions to Conferences
2012Reduction of Pu(VI) by FeCARBOL Paul; WEGEN Detlef; WISS Thierry; JANSSEN ARNE; NICHOLL Adrian; CREMER Bert; MALMBECK Rikard; VAN WINCKEL Stefaan; APOSTOLIDIS Christos; ALVAREZ SARANDES LAVANDERA Rafael, et alContributions to Conferences
2001Separation of 248Cm from a 252Cf Neutron Source for Production of Cm Targets.MALMBECK R.; APOSTOLIDIS Christos; CARLOS R.; GLATZ Jean paul; MOLINET Roger; MORGENSTERN A.; NICHOLL Adrian felim; PAGLIOSA G.; ROEMER K.; SCHAEDEL M., et alArticles in Journals
2004Sequential Therapy with Cytarabine and Bismuth-213 (213BI)-Labeled-HuM195(Anit-CD33) for Acute Myeloid Leukemia (AML).MULFORD D.a.; PANDIT-TASKAR N.; MC DEVITT M.r.; FINN R.d.; APOSTOLIDIS Christos; MORGENSTERN A.; DIVGI C.r.; LARSON S.m.; SCHEINBERG D.a.; JURCIC J.g.Contributions to Conferences
2002Single-Column Extraction Chromatographic Separation of U, Np, Pu and Am.MORGENSTERN A.; APOSTOLIDIS Christos; CARLOS-MARQUEZ R.; MAYER Klaus; MOLINET RogerArticles in Journals
2009Spectroscopic Study of the Interaction of U(VI) with Transferrin and Albumin for Speciation of U(VI) under Blood Serum ConditionsMONTAVON Gilles; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; REPINC Urska; MORGENSTERN AlfredArticles in Journals
2010SrNp(PO4)2: an Original Ordered Modification of CheralitePOPA Karin; WALLEZ G; RAISON Philippe; BREGIROUX D.; APOSTOLIDIS Christos; LINDQVIST-REIS Patric; KONINGS RudyArticles in Journals
2000Structure and Properties of Hydrated La(III), Nd(III) and Er(III) Methanesulonates.ARICO E.m.; ZINNER L.b.; KANELLAKOPOULOS Basil; DORNBERGER Ernst; REBIZANT Jean; APOSTOLIDIS ChristosContributions to Conferences
2001Structure and Properties of Hydrated La(III), Nd(III) and Er(III) Methanosulfonates.ARICO E.m.; ZINNER L.b.; KANELLAKOPOULOS Basil; DORNBERGER Ernst; REBIZANT Jean; APOSTOLIDIS ChristosArticles in Journals
2007The Structures and Optical Spectra of Hydrated Transplutonium Ions in the Solid State and in SolutionLINDQVIST-REIS P.; APOSTOLIDIS CHRISTOS; REBIZANT JEAN; MORGENSTERN ALFRED; KLENZE R.; WALTER O.; FANGHAENEL THOMAS; HAIRE R.g.Articles in Journals
1997Structures of the Anhydrous Yb(III) and the Hydrated Ce(III), Sm(III) and Tb(III) Methanesulfonates.ARICO E.m.; ZINNER L.b.; APOSTOLIDIS Christos; DORNBERGER Ernst; REBIZANT JeanArticles in Journals
2000Studies on the Red Marrow Dosimetry in Radioimmunotherapy. An Experimental Investigation of Factors Influencing the Radio-Induced Myelotoxicity in Therapy with beta-, Auger/Conversion Electron-, or alpha-Emitters.BEHR T.m.; SGOUROS G.; STABIN M.g.; BEHE M.; ANGERSTEIN Ch.; BLUMENTHAL R.d.; APOSTOLIDIS Christos; MOLINET Roger; SHARKEY R.m.; KOCH Lothar, et alArticles in Journals
2005Synergistic Antitumor Effects of alpha-Radioimmunotherapy and Paclitaxel or Doxorubicin on Human Myeoloma Cells.SUPIOT S.; FAIVRE-CHAUVET A.; THILLAYS F.; GOUARD S.; APOSTOLIDIS Christos; WIJDENES John; BARBET J.; BATAILLE R.; DAVODEAU F.; CHEREL M.Articles in Journals
2012Synthesis and in vitro evaluation of 225Ac-DOTA-SubstanceP for targeted alpha therapy of glioblastoma multiformeMAJKOWSKA AGNIESZKA; BRUCHERTSEIFER Frank; WEIS Mirjam; BONELLI Milton; LAURENZA M; APOSTOLIDIS Christos; MORGENSTERN AlfredContributions to Conferences
1998Synthesis and Magnetic Properties of (C5H5)3Ce-Center-HMPA.ARICO E.m.; APOSTOLIDIS Christos; ZINNER L.b.Articles in Journals
2013Synthesis of 213Bi-DOTATOC for peptide receptor a-therapy of GEP-NET patients refractory to β-therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
2012Synthesis of 213Bi-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapyMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
Showing results 95 to 114 of 139

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top